Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner
Impilo invests in Pelago Bioscience AB and enters a partnership with the Founders to accelerate platform expansion. Pelago is a fast-growing drug discovery focused contract research organisation (“CRO”) with a service offering centered around its patented CEllular Thermal Shift Assay (CETSA®) technology. CETSA® provides unique value to customers in accelerating drug discovery projects given its ability to quantify how a drug compound binds to its intended target and perturb the biology in whole-cell physiological conditions. The Company enjoys strong market tailwinds, serves a steadily growing global customer base of leading pharmaceutical and biotechnology companies from its state-of-the-art laboratory in Stockholm, and is well-positioned to capture a significantly larger share of drug discovery projects globally.
Read moreNews
Scantox Group acquires Gentronix
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”), well recognized for its high-quality genetic toxicology services and strong scientific engagement.
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.